Finland· FI-REL-REL14199

Accolate

A zafirlukast product containing zafirlukast, registered in Finland by AstraZeneca Oy. The same ATC class is registered in 5 of our 19 countries.

ATC R03DC01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedAccolateATCR03DC01REGISTER NO.FI-REL-REL14199PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Zafirlukast is registered in 5 of 19 countries.

Countries holding a registration under ATC R03DC01 (zafirlukast), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 4 of them publish a price we can compare per daily dose

Zafirlukast · ATC R03DC01

5 / 19 countries

  • Belgiumprice
  • Finlandprice
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Zafirlukast
Manufacturer
AstraZeneca Oy
Country
Finland (FI)
ATC code
R03DC01
ATC class
Zafirlukast
Defined daily dose
40 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

459 interactions on record for zafirlukast.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Zafirlukast · interactions on record

459 records

  • 15 severe
  • 265 moderate
  • 20 minor
  • 159 info

Most severe, free to view

  • LonafarnibA16AX20severe
  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b92a746a-8020-4f22-a26f-798cde9bac09
GET /v1/drugs/b92a746a-8020-4f22-a26f-798cde9bac09?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "40",
  "form": "tabletti, kalvopäällysteinen",
  "route": null,
  "ddd_unit": "mg",
  "strength": "10 mg",
  "atc_label": "tsafirlukasti",
  "ma_number": "16090",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL14199",
  "authorised_at": "2001-05-21"
}

See everything about zafirlukast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.